- Home
- netherlands antilles
- Equipment
Refine by
Galapagos Medical Equipment & Supplies In Netherlands Antilles
5 equipment items found
Manufactured by:Galapagos NV based inMechelen, BELGIUM
A TYK2 inhibitor for which topline results from the Phase 1b in psoriasis were reported in July 2021. Phase 2 studies in dermatomyositis and Systemic Lupus Erythematosus (SLE) are expected to start in ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
GlaxoSmithKline exercised its option to exclusively license investigational compound GLPG0778 and its corresponding back-up compound GLPG0555, both discovered and developed within GSKs immuno-inflammatory alliance with Galapagos. GSK has all rights to these compounds, and Galapagos is eligible to receive milestones and up to double-digit royalties on global sales. In the course of 2013, GSK ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
The SIK program is a strategic effort to develop assets inhibiting salt-inducible kinases (SIK) as a novel target class in inflammation which we discovered with our proprietary target discovery platform. These molecules inhibit the different members of the SIK family and have shown the potential to modulate anti-inflammatory cytokines and pro-inflammatory cytokines. Targeted and selective ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
GLPG2737 is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) inhibitor which was observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement for patients with autosomal dominant polycystic kidney disease (ADPKD). In December 2020, we announced the first dosing with GLPG2737 in ...